AFTX 201
Alternative Names: AFTX-201Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator AFFINIA THERAPEUTICS
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action BAG3 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dilated cardiomyopathy
Most Recent Events
- 13 Nov 2024 Affinia Therapeutics enters into a manufacturing agreement with Forge Biologics for AFTX 201
- 22 Oct 2024 Preclinical trials in Dilated cardiomyopathy in USA (IV) before October 2024
- 22 Oct 2024 Pharmacodynamics data from a preclinical trial in Dilated cardiomyopathy released by Affinia Therapeutics